Investors in pain management drug developer QRxPharma face a nervous wait until May for a decision from the US regulator that could make or break the company.
An application for the company’s Moxduo Immediate Release pain drug, which is a combination of morphine and oxycodone, will be either approved or rejected by May 25, ending a long and bumpy ride for investors in the biotechnology stock.
Loading...
Jessica Gardner is Deputy editor - News. She has previously edited the Companies and Markets section. Connect with Jessica on Twitter. Email Jessica at jgardner@afr.com
